What Makes Camden National a New Strong Buy Stock

    Date:

    Investors might want to bet on Camden National CAC, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates — one of the most powerful forces impacting stock prices.

    A company’s changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate — the consensus measure of EPS estimates from the sell-side analysts covering the stock — for the current and following years.

    The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

    Therefore, the Zacks rating upgrade for Camden National basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

    Most Powerful Force Impacting Stock Prices

    The change in a company’s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company’s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

    For Camden National, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company’s underlying business. And investors’ appreciation of this improving business trend should push the stock higher.

    Harnessing the Power of Earnings Estimate Revisions

    Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

    The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.

    Earnings Estimate Revisions for Camden National

    This bank is expected to earn $3.33 per share for the fiscal year ending December 2024, which represents a year-over-year change of -8.3%.

    Analysts have been steadily raising their estimates for Camden National. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.4%.

    Bottom Line

    Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of ‘buy’ and ‘sell’ ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a ‘Strong Buy’ rating and the next 15% get a ‘Buy’ rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

    The upgrade of Camden National to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

    To read this article on Zacks.com click here.

    Market News and Data brought to you by Benzinga APIs

    Go Source

    Chart

    SignUp For Breaking Alerts

    New Graphic

    We respect your email privacy

    Share post:

    Popular

    More like this
    Related

    Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

    Gilead Sciences Inc. GILD has voluntarily recalled one lot...

    Alibaba Shares Are Trading Higher: What’s Going On

    Alibaba Group Holding Limited BABA shares are trading higher...

    Why Orgenesis (ORGS) Stock Is Down 23% Today

    Orgenesis Inc ORGS shares are trading lower by 21%...

    2 Billionaire-Held Stocks to Buy Before 2025

    Bill Ackman and Warren Buffett see value in these...